{"id":145659,"date":"2026-08-14T06:58:12","date_gmt":"2026-08-14T06:58:12","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/145659\/"},"modified":"2026-08-14T06:58:12","modified_gmt":"2026-08-14T06:58:12","slug":"novo-nordisk-cpsenovo-b-sees-new-pressure-in-weight-loss-drugs","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/145659\/","title":{"rendered":"Novo Nordisk (CPSE:NOVO B) Sees New Pressure In Weight Loss Drugs"},"content":{"rendered":"\n

Track your investments for FREE<\/a> with Simply Wall St, the portfolio command center trusted by over 7 million individual investors worldwide. <\/p>\n

Novo Nordisk (CPSE:NOVO B) faces fresh competition as the UK’s MHRA approves Eli Lilly’s oral weight loss therapy Foundayo for use in the country. <\/p>\n

The approval adds a non injectable option alongside Novo Nordisk’s GLP 1 based obesity drugs and could affect demand patterns if Foundayo is adopted in public healthcare settings. <\/p>\n

In the US, Amazon Pharmacy launches a new Medicare weight loss drug program priced at $50 per month that will include Novo Nordisk and Eli Lilly medications. <\/p>\n

These developments highlight changing access and pricing dynamics in obesity care that may influence volumes and reimbursement for Novo Nordisk’s flagship treatments. <\/p>\n

Novo Nordisk is far from the only stock tied into this kind of healthcare and infrastructure build out, so it can be useful to compare it with the broader set available through 55 AI infrastructure stocks<\/a>. <\/p>\n

\"CPSE:NOVO<\/a> CPSE:NOVO B 1-Year Stock Price Chart <\/p>\n

Novo Nordisk, a pharmaceuticals group with a DKK1.3 trillion market cap, focuses on researching, manufacturing and distributing treatments for chronic conditions such as obesity and diabetes. As oral and lower cost weight loss options emerge, investors are watching how the company positions its existing GLP 1 portfolio in this broader obesity care market. <\/p>\n

Is Novo Nordisk’s balance sheet strong enough for future acquisitions? Dive into our detailed financial health analysis.<\/a> <\/p>\n

What the Foundayo approval and Amazon program really test in the Novo Nordisk Narrative <\/p>\n

The Novo Nordisk Narrative is built on GLP-1 leadership expanding into convenient pills and new access channels, while holding on to pricing power and earnings quality. The UK approval of Eli Lilly’s Foundayo and Amazon’s low fixed Medicare pricing both push directly on that trade off. <\/p>\n

“Growing pricing pressures, generic competition, and rising costs threaten margins, revenue growth, and earnings stability despite Novo Nordisk’s leadership in obesity and diabetes therapies…” <\/p>\n

Read the full Novo Nordisk narrative<\/a> to see the case behind these numbers<\/a> <\/p>\n

The MHRA green light for Lilly’s oral Foundayo goes straight to the core bet that Novo Nordisk can extend its GLP-1 leadership into pills and implants. It reinforces the Narrative’s risk that pricing pressure could bite as more oral options arrive, especially if NICE backs either drug for broad NHS use. <\/p>\n

Amazon Pharmacy’s US$50 Medicare program points to the other side of the story. Access may widen for both Novo Nordisk and Eli Lilly, yet the flat fee structure speaks directly to analysts’ concerns about lower realised prices and higher non cash items affecting earnings quality that is already flagged as a risk. <\/p>\n

The same regulatory and access news can look like volume upside or margin compression, depending on which version of the Novo Nordisk Narrative you believe. That is where the community discussion can be useful for investors weighing this update. To ensure you’re always in the loop on how the latest news impacts the investment narrative for Novo Nordisk, head to the community page for Novo Nordisk<\/a> to never miss an update on the top community narratives. <\/p>\n

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. <\/p>\n

Companies discussed in this article include NOVO-B.CO<\/a>. <\/p>\n

Have feedback on this article? Concerned about the content? Get in touch<\/a> with us directly. Alternatively, email editorial-team@simplywallst.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"Track your investments for FREE with Simply Wall St, the portfolio command center trusted by over 7 million…\n","protected":false},"author":2,"featured_media":145660,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[271],"tags":[41850,69408,19920,276,272],"class_list":["post-145659","post","type-post","status-publish","format-standard","has-post-thumbnail","category-novo-nordisk","tag-amazon-pharmacy","tag-amazon-program","tag-earnings-quality","tag-eli-lilly","tag-novo-nordisk"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@dk\/117092568710857371","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/145659","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=145659"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/145659\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/145660"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=145659"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=145659"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=145659"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}